{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:45:39Z","timestamp":1789245939684,"version":"build-2803163510"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA006516"],"award-info":[{"award-number":["P30 CA006516"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5 P50 CA89393"],"award-info":[{"award-number":["5 P50 CA89393"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s10549-022-06562-y","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T01:02:48Z","timestamp":1651107768000},"page":"65-78","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II\u2013III and metastatic breast cancers"],"prefix":"10.1007","volume":"194","clinical-trial-number":[{"clinical-trial-number":"nct00317603","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00880464","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3870-5730","authenticated-orcid":false,"given":"Karen S.","family":"Anderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy K.","family":"Erick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meixuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Daley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolonda","family":"Colson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Mihm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Labib R.","family":"Zakka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Hopper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Winer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Dranoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Overmoyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"key":"6562_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/bs.ai.2016.01.001","volume":"130","author":"JP Ward","year":"2016","unstructured":"Ward JP, Gubin MM, Schreiber RD (2016) The role of neoantigens in naturally occurring and therapeutically induced immune responses to cancer. Adv Immunol 130:25\u201374. https:\/\/doi.org\/10.1016\/bs.ai.2016.01.001","journal-title":"Adv Immunol"},{"key":"6562_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41541-019-0103-y","volume":"4","author":"RE Hollingsworth","year":"2019","unstructured":"Hollingsworth RE, Jansen K (2019) Turning the corner on therapeutic cancer vaccines. NPJ Vaccin 4:7. https:\/\/doi.org\/10.1038\/s41541-019-0103-y","journal-title":"NPJ Vaccin"},{"issue":"6382","key":"6562_CR3","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1126\/science.aar7112","volume":"359","author":"U Sahin","year":"2018","unstructured":"Sahin U, Tureci O (2018) Personalized vaccines for cancer immunotherapy. Science 359(6382):1355\u20131360. https:\/\/doi.org\/10.1126\/science.aar7112","journal-title":"Science"},{"key":"6562_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/2051-1426-2-11","volume":"2","author":"HL Kaufman","year":"2014","unstructured":"Kaufman HL, Ruby CE, Hughes T, Slingluff CL Jr (2014) Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J Immunother Cancer 2:11. https:\/\/doi.org\/10.1186\/2051-1426-2-11","journal-title":"J Immunother Cancer"},{"issue":"8","key":"6562_CR5","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1073\/pnas.90.8.3539","volume":"90","author":"G Dranoff","year":"1993","unstructured":"Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90(8):3539\u20133543. https:\/\/doi.org\/10.1073\/pnas.90.8.3539","journal-title":"Proc Natl Acad Sci USA"},{"issue":"13","key":"6562_CR6","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.1158\/1078-0432.CCR-06-2937","volume":"13","author":"EJ Small","year":"2007","unstructured":"Small EJ, Sacks N, Nemunaitis J, Urba WJ, Dula E, Centeno AS, Nelson WG, Ando D, Howard C, Borellini F, Nguyen M, Hege K, Simons JW (2007) Granulocyte macrophage colony-stimulating factor\u2013secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 13(13):3883\u20133891. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-2937","journal-title":"Clin Cancer Res"},{"issue":"18","key":"6562_CR7","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1200\/jco.2007.25.18_suppl.3010","volume":"25","author":"D Laheru","year":"2007","unstructured":"Laheru D, Yeo C, Biedrzycki B, Solt S, Lutz E, Onners B, Tartakovsky I, Herman J, Hruban R, Piantadosi S, Jaffee E (2007) A safety and efficacy trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene in combination with adjuvant chemoradiotherapy for the treatment of adenocarcinoma of the pancreas. J Clin Oncol 25(18):3010\u20133010. https:\/\/doi.org\/10.1200\/jco.2007.25.18_suppl.3010","journal-title":"J Clin Oncol"},{"issue":"35","key":"6562_CR8","doi-asserted-by":"publisher","first-page":"5911","DOI":"10.1200\/JCO.2009.23.3494","volume":"27","author":"LA Emens","year":"2009","unstructured":"Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M, Levi J, Daphtary MM, Biedrzycki B, Wolff AC, Stearns V, Disis ML, Ye X, Piantadosi S, Fetting JH, Davidson NE, Jaffee EM (2009) Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 27(35):5911\u20135918. https:\/\/doi.org\/10.1200\/JCO.2009.23.3494","journal-title":"J Clin Oncol"},{"issue":"10","key":"6562_CR9","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1158\/2326-6066.CIR-14-0058","volume":"2","author":"G Chen","year":"2014","unstructured":"Chen G, Gupta R, Petrik S, Laiko M, Leatherman JM, Asquith JM, Daphtary MM, Garrett-Mayer E, Davidson NE, Hirt K, Berg M, Uram JN, Dauses T, Fetting J, Duus EM, Atay-Rosenthal S, Ye X, Wolff AC, Stearns V, Jaffee EM, Emens LA (2014) A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. Cancer Immunol Res 2(10):949\u2013961. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0058","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"6562_CR10","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1200\/JCO.2003.03.091","volume":"21","author":"R Salgia","year":"2003","unstructured":"Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, Hodi FS, Jaklitsch M, Mentzer S, Swanson S, Lukanich J, Bueno R, Wain J, Mathisen D, Wright C, Fidias P, Donahue D, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Sugarbaker D, Mihm M, Dranoff G (2003) Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 21(4):624\u2013630. https:\/\/doi.org\/10.1200\/JCO.2003.03.091","journal-title":"J Clin Oncol"},{"issue":"22","key":"6562_CR11","doi-asserted-by":"publisher","first-page":"13141","DOI":"10.1073\/pnas.95.22.13141","volume":"95","author":"R Soiffer","year":"1998","unstructured":"Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC, Hodi FS, Liebster L, Lam P, Mentzer S, Singer S, Tanabe KK, Cosimi AB, Duda R, Sober A, Bhan A, Daley J, Neuberg D, Parry G, Rokovich J, Richards L, Drayer J, Berns A, Clift S, Cohen LK, Mulligan RC, Dranoff G (1998) Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 95(22):13141\u201313146","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"6562_CR12","first-page":"756","volume":"1","author":"J Nemunaitis","year":"2006","unstructured":"Nemunaitis J, Murray N (2006) Immune-modulating vaccines in non-small cell lung cancer. J Thorac Oncol 1(7):756\u2013761","journal-title":"J Thorac Oncol"},{"issue":"3","key":"6562_CR13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ccr.2007.01.013","volume":"11","author":"M Shipitsin","year":"2007","unstructured":"Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, Richardson AL, Schnitt SJ, Nikolsky Y, Gelman RS, Polyak K (2007) Molecular definition of breast tumor heterogeneity. Cancer Cell 11(3):259\u2013273. https:\/\/doi.org\/10.1016\/j.ccr.2007.01.013","journal-title":"Cancer Cell"},{"issue":"17","key":"6562_CR14","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1200\/JCO.2003.07.005","volume":"21","author":"R Soiffer","year":"2003","unstructured":"Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S, Tanabe K, Duda R, Mentzer S, Jaklitsch M, Bueno R, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Mihm M, Dranoff G (2003) Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 21(17):3343\u20133350. https:\/\/doi.org\/10.1200\/JCO.2003.07.005","journal-title":"J Clin Oncol"},{"issue":"4","key":"6562_CR15","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1021\/pr700804c","volume":"7","author":"KS Anderson","year":"2008","unstructured":"Anderson KS, Ramachandran N, Wong J, Raphael JV, Hainsworth E, Demirkan G, Cramer D, Aronzon D, Hodi FS, Harris L, Logvinenko T, LaBaer J (2008) Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. J Proteome Res 7(4):1490\u20131499. https:\/\/doi.org\/10.1021\/pr700804c","journal-title":"J Proteome Res"},{"key":"6562_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/978-1-0716-1562-1_4","volume":"2344","author":"L Song","year":"2021","unstructured":"Song L, Wiktor P, Qiu J, LaBaer J (2021) Identification of antibody biomarker using high-density nucleic acid programmable protein array. Methods Mol Biol 2344:47\u201364. https:\/\/doi.org\/10.1007\/978-1-0716-1562-1_4","journal-title":"Methods Mol Biol"},{"issue":"3","key":"6562_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1021\/pr050395r","volume":"5","author":"AE Witt","year":"2006","unstructured":"Witt AE, Hines LM, Collins NL, Hu Y, Gunawardane RN, Moreira D, Raphael J, Jepson D, Koundinya M, Rolfs A, Taron B, Isakoff SJ, Brugge JS, LaBaer J (2006) Functional proteomics approach to investigate the biological activities of cDNAs implicated in breast cancer. J Proteome Res 5(3):599\u2013610. https:\/\/doi.org\/10.1021\/pr050395r","journal-title":"J Proteome Res"},{"issue":"1","key":"6562_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ygyno.2017.04.005","volume":"146","author":"BA Katchman","year":"2017","unstructured":"Katchman BA, Chowell D, Wallstrom G, Vitonis AF, LaBaer J, Cramer DW, Anderson KS (2017) Autoantibody biomarkers for the detection of serous ovarian cancer. Gynecol Oncol 146(1):129\u2013136. https:\/\/doi.org\/10.1016\/j.ygyno.2017.04.005","journal-title":"Gynecol Oncol"},{"issue":"12","key":"6562_CR19","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1158\/1078-0432.CCR-15-2163","volume":"22","author":"WT Curry Jr","year":"2016","unstructured":"Curry WT Jr, Gorrepati R, Piesche M, Sasada T, Agarwalla P, Jones PS, Gerstner ER, Golby AJ, Batchelor TT, Wen PY, Mihm MC, Dranoff G (2016) Vaccination with irradiated autologous tumor cells mixed with irradiated GM-K562 cells stimulates antitumor immunity and T lymphocyte activation in patients with recurrent malignant glioma. Clin Cancer Res 22(12):2885\u20132896. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2163","journal-title":"Clin Cancer Res"},{"issue":"8","key":"6562_CR20","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1073\/pnas.0712237105","volume":"105","author":"FS Hodi","year":"2008","unstructured":"Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, Korman A, Lautz D, Russell S, Jaklitsch MT, Ramaiya N, Chen TC, Neuberg D, Allison JP, Mihm MC, Dranoff G (2008) Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 105(8):3005\u20133010. https:\/\/doi.org\/10.1073\/pnas.0712237105","journal-title":"Proc Natl Acad Sci USA"},{"issue":"14","key":"6562_CR21","doi-asserted-by":"publisher","first-page":"3178","DOI":"10.1158\/1078-0432.CCR-14-2932","volume":"21","author":"JM Goldberg","year":"2015","unstructured":"Goldberg JM, Fisher DE, Demetri GD, Neuberg D, Allsop SA, Fonseca C, Nakazaki Y, Nemer D, Raut CP, George S, Morgan JA, Wagner AJ, Freeman GJ, Ritz J, Lezcano C, Mihm M, Canning C, Hodi FS, Dranoff G (2015) Biologic activity of autologous, granulocyte-macrophage colony-stimulating factor secreting alveolar soft-part sarcoma and clear cell sarcoma vaccines. Clin Cancer Res 21(14):3178\u20133186. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2932","journal-title":"Clin Cancer Res"},{"issue":"8","key":"6562_CR22","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1073\/pnas.0830997100","volume":"100","author":"FS Hodi","year":"2003","unstructured":"Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, Allison JP, Dranoff G (2003) Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 100(8):4712\u20134717. https:\/\/doi.org\/10.1073\/pnas.0830997100","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6562_CR23","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1034\/j.1600-065x.2002.18813.x","volume":"188","author":"G Dranoff","year":"2002","unstructured":"Dranoff G (2002) GM-CSF-based cancer vaccines. Immunol Rev 188:147\u2013154. https:\/\/doi.org\/10.1034\/j.1600-065x.2002.18813.x","journal-title":"Immunol Rev"},{"issue":"3","key":"6562_CR24","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/ijc.31335","volume":"143","author":"R Kaaks","year":"2018","unstructured":"Kaaks R, Fortner RT, Husing A, Barrdahl M, Hopper M, Johnson T, Tjonneland A, Hansen L, Overvad K, Fournier A, Boutron-Ruault MC, Kvaskoff M, Dossus L, Johansson M, Boeing H, Trichopoulou A, Benetou V, La Vecchia C, Sieri S, Mattiello A, Palli D, Tumino R, Matullo G, Onland-Moret NC, Gram IT, Weiderpass E, Sanchez MJ, Navarro Sanchez C, Duell EJ, Ardanaz E, Larranaga N, Lundin E, Idahl A, Jirstrom K, Nodin B, Travis RC, Riboli E, Merritt M, Aune D, Terry K, Cramer DW, Anderson KS (2018) Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation. Int J Cancer 143(3):515\u2013526. https:\/\/doi.org\/10.1002\/ijc.31335","journal-title":"Int J Cancer"},{"issue":"2","key":"6562_CR25","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1677\/joe.1.06871","volume":"190","author":"N Hattori","year":"2006","unstructured":"Hattori N, Nakayama Y, Kitagawa K, Ishihara T, Saiki Y, Inagaki C (2006) Anti-prolactin (PRL) autoantibody-binding sites (epitopes) on PRL molecule in macroprolactinemia. J Endocrinol 190(2):287\u2013293. https:\/\/doi.org\/10.1677\/joe.1.06871","journal-title":"J Endocrinol"},{"issue":"16","key":"6562_CR26","doi-asserted-by":"publisher","first-page":"5993","DOI":"10.1158\/1078-0432.CCR-05-0018","volume":"11","author":"MR Weihrauch","year":"2005","unstructured":"Weihrauch MR, Ansen S, Jurkiewicz E, Geisen C, Xia Z, Anderson KS, Gracien E, Schmidt M, Wittig B, Diehl V, Wolf J, Bohlen H, Nadler LM (2005) Phase I\/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. Clin Cancer Res 11(16):5993\u20136001. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-0018","journal-title":"Clin Cancer Res"},{"issue":"9","key":"6562_CR27","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1182\/blood-2003-05-1374","volume":"102","author":"B Maecker","year":"2003","unstructured":"Maecker B, Sherr DH, Vonderheide RH, von Bergwelt-Baildon MS, Hirano N, Anderson KS, Xia Z, Butler MO, Wucherpfennig KW, O\u2019Hara C, Cole G, Kwak SS, Ramstedt U, Tomlinson AJ, Chicz RM, Nadler LM, Schultze JL (2003) The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood 102(9):3287\u20133294. https:\/\/doi.org\/10.1182\/blood-2003-05-1374","journal-title":"Blood"},{"issue":"2","key":"6562_CR28","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.4049\/jimmunol.163.2.1037","volume":"163","author":"Y Rongcun","year":"1999","unstructured":"Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, Maes H, Kono K, Hising C, Petersson M, Larsson O, Lan L, Appella E, Sette A, Celis E, Kiessling R (1999) Identification of new HER2\/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol 163(2):1037\u20131044","journal-title":"J Immunol"},{"issue":"3","key":"6562_CR29","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00262-006-0191-1","volume":"56","author":"MS Mitchell","year":"2007","unstructured":"Mitchell MS, Lund TA, Sewell AK, Marincola FM, Paul E, Schroder K, Wilson DB, Kan-Mitchell J (2007) The cytotoxic T cell response to peptide analogs of the HLA-A*0201-restricted MUC1 signal sequence epitope, M12. Cancer Immunol Immunother 56(3):287\u2013301. https:\/\/doi.org\/10.1007\/s00262-006-0191-1","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"6562_CR30","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1002\/eji.200425297","volume":"34","author":"G Held","year":"2004","unstructured":"Held G, Matsuo M, Epel M, Gnjatic S, Ritter G, Lee SY, Tai TY, Cohen CJ, Old LJ, Pfreundschuh M, Reiter Y, Hoogenboom HR, Renner C (2004) Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide\/MHC-specific antibody fragments. Eur J Immunol 34(10):2919\u20132929. https:\/\/doi.org\/10.1002\/eji.200425297","journal-title":"Eur J Immunol"},{"issue":"16","key":"6562_CR31","first-page":"5964","volume":"61","author":"MH Andersen","year":"2001","unstructured":"Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC, thor Straten P, (2001) Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 61(16):5964\u20135968","journal-title":"Cancer Res"},{"key":"6562_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gki452","author":"GL Zhang","year":"2005","unstructured":"Zhang GL, Khan AM, Srinivasan KN, August JT, Brusic V (2005) MULTIPRED: a computational system for prediction of promiscuous HLA binding peptides. Nucleic Acids Res (Web Server issue). https:\/\/doi.org\/10.1093\/nar\/gki452","journal-title":"Nucleic Acids Res (Web Server issue)"},{"issue":"12","key":"6562_CR33","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.vaccine.2009.01.089","volume":"27","author":"S Mirshahidi","year":"2009","unstructured":"Mirshahidi S, Kramer VG, Whitney JB, Essono S, Lee S, Dranoff G, Anderson KS, Ruprecht RM (2009) Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: prolonged survival. Vaccine 27(12):1825\u20131833. https:\/\/doi.org\/10.1016\/j.vaccine.2009.01.089","journal-title":"Vaccine"},{"issue":"5","key":"6562_CR34","first-page":"362","volume":"1","author":"D Porter","year":"2003","unstructured":"Porter D, Lahti-Domenici J, Keshaviah A, Bae YK, Argani P, Marks J, Richardson A, Cooper A, Strausberg R, Riggins GJ, Schnitt S, Gabrielson E, Gelman R, Polyak K (2003) Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res 1(5):362\u2013375","journal-title":"Mol Cancer Res"},{"issue":"21","key":"6562_CR35","doi-asserted-by":"publisher","first-page":"12033","DOI":"10.1073\/pnas.96.21.12033","volume":"96","author":"W Herr","year":"1999","unstructured":"Herr W, Ranieri E, Gambotto A, Kierstead LS, Amoscato AA, Gesualdo L, Storkus WJ (1999) Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood. Proc Natl Acad Sci USA 96(21):12033\u201312038. https:\/\/doi.org\/10.1073\/pnas.96.21.12033","journal-title":"Proc Natl Acad Sci USA"},{"issue":"22","key":"6562_CR36","doi-asserted-by":"publisher","first-page":"9031","DOI":"10.1158\/0008-5472.CAN-10-0699","volume":"70","author":"S Kreiter","year":"2010","unstructured":"Kreiter S, Selmi A, Diken M, Koslowski M, Britten CM, Huber C, Tureci O, Sahin U (2010) Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 70(22):9031\u20139040. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-0699","journal-title":"Cancer Res"},{"issue":"2","key":"6562_CR37","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","volume":"183","author":"PA Ott","year":"2020","unstructured":"Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad MM, Hellmann MD, Lin JJ, Friedlander T, Bushway ME, Balogh KN, Sciuto TE, Kohler V, Turnbull SJ, Besada R, Curran RR, Trapp B, Scherer J, Poran A, Harjanto D, Barthelme D, Ting YS, Dong JZ, Ware Y, Huang Y, Huang Z, Wanamaker A, Cleary LD, Moles MA, Manson K, Greshock J, Khondker ZS, Fritsch E, Rooney MS, DeMario M, Gaynor RB, Srinivasan L (2020) A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell 183(2):347\u2013362. https:\/\/doi.org\/10.1016\/j.cell.2020.08.053","journal-title":"Cell"},{"issue":"7662","key":"6562_CR38","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Lower M, Bukur V, Tadmor AD, Luxemburger U, Schrors B, Omokoko T, Vormehr M, Albrecht C, Paruzynski A, Kuhn AN, Buck J, Heesch S, Schreeb KH, Muller F, Ortseifer I, Vogler I, Godehardt E, Attig S, Rae R, Breitkreuz A, Tolliver C, Suchan M, Martic G, Hohberger A, Sorn P, Diekmann J, Ciesla J, Waksmann O, Bruck AK, Witt M, Zillgen M, Rothermel A, Kasemann B, Langer D, Bolte S, Diken M, Kreiter S, Nemecek R, Gebhardt C, Grabbe S, Holler C, Utikal J, Huber C, Loquai C, Tureci O (2017) Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547(7662):222\u2013226. https:\/\/doi.org\/10.1038\/nature23003","journal-title":"Nature"},{"issue":"11","key":"6562_CR39","doi-asserted-by":"publisher","first-page":"5976","DOI":"10.1172\/JCI134915","volume":"130","author":"G Cafri","year":"2020","unstructured":"Cafri G, Gartner JJ, Zaks T, Hopson K, Levin N, Paria BC, Parkhurst MR, Yossef R, Lowery FJ, Jafferji MS, Prickett TD, Goff SL, McGowan CT, Seitter S, Shindorf ML, Parikh A, Chatani PD, Robbins PF, Rosenberg SA (2020) mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J Clin Invest 130(11):5976\u20135988. https:\/\/doi.org\/10.1172\/JCI134915","journal-title":"J Clin Invest"},{"issue":"4","key":"6562_CR40","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A (2017) Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168(4):707\u2013723. https:\/\/doi.org\/10.1016\/j.cell.2017.01.017","journal-title":"Cell"},{"issue":"6","key":"6562_CR41","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1002\/(sici)1097-0215(19980610)76:6<817::aid-ijc9>3.0.co;2-0","volume":"76","author":"M Reddish","year":"1998","unstructured":"Reddish M, MacLean GD, Koganty RR, Kan-Mitchell J, Jones V, Mitchell MS, Longenecker BM (1998) Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide. Int J Cancer 76(6):817\u2013823. https:\/\/doi.org\/10.1002\/(sici)1097-0215(19980610)76:6%3c817::aid-ijc9%3e3.0.co;2-0","journal-title":"Int J Cancer"},{"issue":"4","key":"6562_CR42","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1172\/JCI11752","volume":"107","author":"KL Knutson","year":"2001","unstructured":"Knutson KL, Schiffman K, Disis ML (2001) Immunization with a HER-2\/neu helper peptide vaccine generates HER-2\/neu CD8 T-cell immunity in cancer patients. J Clin Invest 107(4):477\u2013484. https:\/\/doi.org\/10.1172\/JCI11752","journal-title":"J Clin Invest"},{"issue":"9","key":"6562_CR43","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/79519","volume":"6","author":"SK Nair","year":"2000","unstructured":"Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, Lebkowski JS, Vieweg J, Gilboa E (2000) Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 6(9):1011\u20131017. https:\/\/doi.org\/10.1038\/79519","journal-title":"Nat Med"},{"issue":"3","key":"6562_CR44","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","volume":"16","author":"JS O'Donnell","year":"2019","unstructured":"O\u2019Donnell JS, Teng MWL, Smyth MJ (2019) Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol 16(3):151\u2013167. https:\/\/doi.org\/10.1038\/s41571-018-0142-8","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"6562_CR45","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41576-019-0114-6","volume":"20","author":"S Turajlic","year":"2019","unstructured":"Turajlic S, Sottoriva A, Graham T, Swanton C (2019) Resolving genetic heterogeneity in cancer. Nat Rev Genet 20(7):404\u2013416. https:\/\/doi.org\/10.1038\/s41576-019-0114-6","journal-title":"Nat Rev Genet"},{"issue":"5","key":"6562_CR46","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, Vonderheide RH, Pittet MJ, Jain RK, Zou W, Howcroft TK, Woodhouse EC, Weinberg RA, Krummel MF (2018) Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 24(5):541\u2013550. https:\/\/doi.org\/10.1038\/s41591-018-0014-x","journal-title":"Nat Med"},{"issue":"9938","key":"6562_CR47","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384(9938):164\u2013172. https:\/\/doi.org\/10.1016\/S0140-6736(13)62422-8","journal-title":"Lancet"},{"issue":"1","key":"6562_CR48","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1021\/pr100686b","volume":"10","author":"KS Anderson","year":"2011","unstructured":"Anderson KS, Sibani S, Wallstrom G, Qiu J, Mendoza EA, Raphael J, Hainsworth E, Montor WR, Wong J, Park JG, Lokko N, Logvinenko T, Ramachandran N, Godwin AK, Marks J, Engstrom P, Labaer J (2011) Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. J Proteome Res 10(1):85\u201396. https:\/\/doi.org\/10.1021\/pr100686b","journal-title":"J Proteome Res"},{"issue":"12","key":"6562_CR49","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1158\/1055-9965.EPI-20-1057","volume":"29","author":"RC Bast Jr","year":"2020","unstructured":"Bast RC Jr, Lu Z, Han CY, Lu KH, Anderson KS, Drescher CW, Skates SJ (2020) Biomarkers and strategies for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 29(12):2504\u20132512. https:\/\/doi.org\/10.1158\/1055-9965.EPI-20-1057","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"12","key":"6562_CR50","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1158\/1055-9965.EPI-20-0331","volume":"29","author":"F Rauf","year":"2020","unstructured":"Rauf F, Anderson KS, LaBaer J (2020) Autoantibodies in early detection of breast cancer. Cancer Epidemiol Biomarkers Prev 29(12):2475\u20132485. https:\/\/doi.org\/10.1158\/1055-9965.EPI-20-0331","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"9","key":"6562_CR51","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1158\/1055-9965.EPI-15-0047","volume":"24","author":"J Wang","year":"2015","unstructured":"Wang J, Figueroa JD, Wallstrom G, Barker K, Park JG, Demirkan G, Lissowska J, Anderson KS, Qiu J, LaBaer J (2015) Plasma autoantibodies associated with basal-like breast cancers. Cancer Epidemiol Biomark Prev 24(9):1332\u20131340. https:\/\/doi.org\/10.1158\/1055-9965.EPI-15-0047","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"9","key":"6562_CR52","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O\u2019Shaughnessy J, Investigators K (2020) Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382(9):810\u2013821. https:\/\/doi.org\/10.1056\/NEJMoa1910549","journal-title":"N Engl J Med"},{"issue":"10265","key":"6562_CR53","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/s0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Schmid P (2020) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396(10265):1817\u20131828. https:\/\/doi.org\/10.1016\/s0140-6736(20)32531-9","journal-title":"Lancet"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06562-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-022-06562-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06562-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T08:31:36Z","timestamp":1744187496000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-022-06562-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["6562"],"URL":"https:\/\/doi.org\/10.1007\/s10549-022-06562-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,28]]},"assertion":[{"value":"15 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GD is an employee of Novartis with stock ownership.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The clinical trial was approved by the Dana-Farber\/Harvard Cancer Center (DF\/HCC) Institutional Review Board (DF\/HCC #05-110; DF\/HCC #08-217; DF\/HCC #05-111\/NCT00317603; DF\/HCC #08-216\/NCT00880464).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients signed written informed consent for tissue harvesting and subsequent vaccinations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Consent for publication was included in the patient consent forms for the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}